Meropenem Steriscience (Meropenem)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, leading to osmotic rupture and bacterial death, and it remains active against many β‑lactamase‑producing organisms.

The prescribed dose of Meropenem Steriscience is determined by the treating physician based on the type and severity of infection, the patient’s renal and hepatic function, age, weight and any concomitant medications. Dosage regimens are individualized and should follow current clinical guidelines.

The safety of Meropenem in pregnancy and lactation has not been definitively established; it is classified as pregnancy category unknown. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when safer options are available.

To order Meropenem Steriscience, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and required import documentation.

Meropenem shares a broad spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers enhanced stability against many β‑lactamases and a slightly lower risk of nephrotoxicity compared with imipenem. Compared with non‑carbapenem agents, it provides superior activity against multidrug‑resistant Gram‑negative bacteria, though cost and local resistance patterns influence selection.

Meropenem Steriscience should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must remain in its original packaging, must not be frozen, and should be gently shaken only if required for reconstitution, following the manufacturer’s instructions.

Meropenem Steriscience is supplied as an injectable solution for intravenous infusion. It is typically administered over a 15‑30‑minute infusion period, with the exact rate and duration determined by the prescribing clinician based on infection severity and patient-specific factors.

Serious adverse events include seizures (especially in patients with renal impairment or pre‑existing CNS disorders), Clostridioides difficile‑associated colitis, severe hypersensitivity reactions such as anaphylaxis, neutropenia or agranulocytosis, and hepatic failure. Prompt medical attention is required if any of these occur.

Meropenem Steriscience is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving concomitant nephrotoxic agents.